Please assess the completion status of the following clinical trial:

Trial Title: Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Baseline BMI between 25 and 35~Exclusion Criteria:~* Individuals with current fMRI contraindications (e.g., metal implants, braces)~* Probable current Axis I psychopathology (e.g., major depression disorder, panic disorder, generalized anxiety disorder, bipolar disorder)~* Habitual use of cigarettes or illicit drugs~* Pregnancy or breastfeeding~* Diagnosis of serious medical problems (e.g., diabetes, cardiovascular disease, stroke)~* Current weight loss dieting and/or weight fluctuations great than 10 lbs in the previous 6 weeks~* Do not consume dairy~* Allergy to bromocriptine, dairy, and nuts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Bromocriptine, then Placebo (Type: OTHER): During the first intervention visit, participants receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Following a 2-week washout period, participants return for the second intervention visit, where they receive 2 capsules of placebo (sugar free calcium supplement) matched in shape (circle) and color (white) to bromocriptine. Both bromocriptine and placebo are administered orally.
- Placebo, then Bromocriptine (Type: OTHER): During the first intervention visit, participants receive 2 capsules of placebo (sugar free calcium supplement). Following a 2-week washout period, participants return for the second intervention visit, where they receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Both bromocriptine and placebo are administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).